EUVIMEDEUVIMED entdecken
Crossref

Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1 -Amplified Breast Cancer

Chaofan Wang, Yan Fang, Ziqin Zhou, Zhuoheng Liu, Fang Feng, Xuan Wan, Yan Li, Shuang Liu, Jian Ding, Zhi-Min Zhang, Hua Xie, Xiaoyun Lu iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Chaofan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Moderni…. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Design, Antineoplastic Agents, Cell Proliferation. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Changjiang Scholar Program, Ministry of Education, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CCNE1 amplification occurs in breast cancer and currently lacks effective therapies. PKMYT1 as a synthetic lethal target for CCNE1 amplification holds promise for the treatment of CCNE1-amplified breast cancer. Herein, we discover a series of 2-amino-[1,1'-biphenyl]-3-carboxamide derivatives as potent and selective PKMYT1 inhibitors using structure-based drug design. The representative compound 8ma exhibited excellent potency against PKMYT1, while sparing WEE1. It also suppressed proliferation of the CCNE1-amplified HCC1569 breast cancer cell line and showed synergistic cytotoxicity in combination with gemcitabine. PKMYT1 X-ray cocrystallography confirmed that introduction of key binding interactions between the inhibitors and residues Asp251 and Tyr121 of PKMYT1 greatly enhanced the potency and selectivity of the compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDrug DesignAntineoplastic AgentsCell ProliferationCyclin EHumansFemaleStructure-Activity RelationshipCell Line, TumorOncogene ProteinsProtein Kinase InhibitorsProtein-Tyrosine KinasesDrug Screening Assays, AntitumorCrystallography, X-RayMembrane ProteinsProtein Serine-Threonine Kinases

Substanzen

PKMYT1 protein, humanAntineoplastic AgentsCCNE1 protein, humanCyclin EOncogene ProteinsProtein Kinase InhibitorsProtein-Tyrosine KinasesMembrane ProteinsProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education,…
  • Division of Antitumor Pharmacology & State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049, China.
  • Department of Hematology, Guangdong Second Provincial General Hospital, Jinan University, Guangzhou 510632, China.
  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
  • Division of Antitumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

ORCID-Profile: Xiaoyun Lu

Förderung

  • Changjiang Scholar Program, Ministry of Education
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China
  • Opening Project of Guangdong Provincial Key Laboratory of New Drug Design and Evaluation

Zitieren

APA

Wang, C., Fang, Y., Zhou, Z., Liu, Z., Feng, F., Wan, X., Li, Y., Liu, S., Ding, J., Zhang, Z. M., Xie, H., & Lu, X. (2024). Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1 -Amplified Breast Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01458

Vancouver

Wang C, Fang Y, Zhou Z, Liu Z, Feng F, Wan X, et al. Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1 -Amplified Breast Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01458

BibTeX
@article{Wang2024,
  author = {Wang, Chaofan and Fang, Yan and Zhou, Ziqin and Liu, Zhuoheng and Feng, Fang and Wan, Xuan and Li, Yan and Liu, Shuang and Ding, Jian and Zhang, Zhi-Min and Xie, Hua and Lu, Xiaoyun},
  title = {Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1 -Amplified Breast Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01458}
}
Kostenlos starten →